CTI BioPharma Corp. (DE) Common Stock
CTIC
CTIC was delisted on the 23rd of June, 2023.
80 hedge funds and large institutions have $58.1M invested in CTI BioPharma Corp. (DE) Common Stock in 2016 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 30 increasing their positions, 20 reducing their positions, and 24 closing their positions.
2,650% more call options, than puts
Call options by funds: $55K | Put options by funds: $2K
50% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 20
15% less funds holding
Funds holding: 94 → 80 (-14)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
58% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 24
65% less capital invested
Capital invested by funds: $165M → $58.1M (-$107M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.35M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$800K |
| 3 |
Millennium Management
New York
|
+$738K |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$315K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$222K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
-$6.51M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$5.56M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$3.93M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.31M |
| 5 |
DM
Deerfield Management
New York
|
-$2.75M |
CTIC Hedge Fund Activity: Q1 2016 in Review
80 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q1 2016, worth a combined $58.1M — down 65% from $165M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of CTIC and 10 opened new positions — a net loss of 14 holders — while 20 trimmed existing stakes and 30 added.
The largest buyer was Vanguard Group, adding an estimated $1.35M. The largest seller was Sio Capital Management, exiting entirely with an estimated $6.51M sold.
- 80 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q1 2016, down from 94 in Q4 2015.
- Funds reported $58.1M of CTI BioPharma Corp. (DE) Common Stock stock for Q1 2016, down 65% quarter-over-quarter.
- 10 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q1 2016 and 24 closed out, a net change of -14 holders.
- The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q1 2016 was Vanguard Group, an estimated $1.35M added.
- The largest CTI BioPharma Corp. (DE) Common Stock seller in Q1 2016 was Sio Capital Management, an estimated $6.51M sold.
Based on aggregated 13F filings for Q1 2016.